Aspirin’s Potential Role in Preventing Aortic Valve Disease for High-Risk Patients
A new observational study in the *European Heart Journal* suggests regular aspirin use may be associated with a significantly lower risk of developing aortic valve calcium and severe aortic stenosis, but only in individuals with high levels of lipoprotein(a) [Lp(a)]. Analyzing data from over 6,500 participants in the Multi-Ethnic Study of Atherosclerosis, researchers found that for people with Lp(a) levels at or above 75 mg/dL, regular aspirin use (≥3 days/week) was linked to a 58% lower risk of aortic valve calcium and a 98% lower risk of severe aortic stenosis. In contrast, no such protective association was found for individuals with elevated LDL cholesterol, highlighting a potentially distinct mechanism for Lp(a)-driven valve disease.
Why it might matter to you:
This research introduces a novel, patient-specific consideration for preventive cardiology. It suggests that a simple, low-cost intervention like aspirin could be strategically targeted based on a specific biomarker (Lp(a)) to potentially mitigate a serious valvular heart condition. For clinicians, it underscores the growing importance of measuring Lp(a) to identify patients who might benefit from a tailored approach to cardiovascular risk reduction beyond standard cholesterol management.
Stay curious. Stay informed — with
Science Briefing.
Always double check the original article for accuracy.
